Acurx Pharmaceuticals (NASDAQ:ACXP) Shares Up 0.9% – Still a Buy?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP)’s share price shot up 0.9% during trading on Wednesday. The company traded as high as $1.18 and last traded at $1.15. Approximately 20,960 shares changed hands during trading, a decline of 76% from the average session volume of 86,732 shares. The stock had previously closed at $1.14.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Thursday, October 15th. HC Wainwright reaffirmed a “buy” rating on shares of Acurx Pharmaceuticals in a research note on Tuesday, September 29th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold”.

Acurx Pharmaceuticals Price Performance

The business’s 50 day simple moving average is $1.34 and its 200 day simple moving average is $1.66. The company has a market capitalization of $6.31 million, a PE ratio of -0.42 and a beta of -2.05.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.15). As a group, analysts anticipate that Acurx Pharmaceuticals, Inc. will post -2.00 EPS for the current year.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for serious bacterial infections. The company’s research is centered on antibacterial compounds designed to address pathogens that are increasingly resistant to existing treatments.

Acurx’s lead product candidate is ibezapolstat, an investigational antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C. difficile or C.